CR20220531A - Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados - Google Patents

Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados

Info

Publication number
CR20220531A
CR20220531A CR20220531A CR20220531A CR20220531A CR 20220531 A CR20220531 A CR 20220531A CR 20220531 A CR20220531 A CR 20220531A CR 20220531 A CR20220531 A CR 20220531A CR 20220531 A CR20220531 A CR 20220531A
Authority
CR
Costa Rica
Prior art keywords
relates
proteins
antibodies
enzyme
derivatives
Prior art date
Application number
CR20220531A
Other languages
English (en)
Inventor
Zhixin Shao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20220531A publication Critical patent/CR20220531A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a proteínas, en particular, anticuerpos, tales como anticuerpos biespecíficos anti-CD20/anti-CD3 y anticuerpos anti-α-sinucleína, que tienen glucanos monogalactosilados (G1) y digalactosilados (G2). Más en particular, la presente invención se refiere a ingeniería de galactosilación para generar proteínas con propiedades terapéuticas mejoradas, que incluyen proteínas con título aumentado. Además, la invención se refiere a un medio de cultivo celular y una célula de mamífero, así como a métodos que usan dicho medio de cultivo celular y dicha célula de mamífero para producir dichas proteínas. Además, la presente invención se refiere al uso de dichos anticuerpos como un medicamento, tal como para el tratamiento de cáncer, en particular, cáncer asociado a linfocitos B, o enfermedad de Parkinson.
CR20220531A 2020-04-24 2021-04-23 Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados CR20220531A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20171356 2020-04-24
PCT/EP2021/060637 WO2021214277A1 (en) 2020-04-24 2021-04-23 Enzyme and pathway modulation with sulfhydryl compounds and their derivatives

Publications (1)

Publication Number Publication Date
CR20220531A true CR20220531A (es) 2022-11-28

Family

ID=70464886

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20220531A CR20220531A (es) 2020-04-24 2021-04-23 Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados
CR20250142A CR20250142A (es) 2020-04-24 2021-04-23 Modulación de enzimas y vías con compuestos de sulfhidrilo y sus derivados (divisional exp. 2022-0531)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20250142A CR20250142A (es) 2020-04-24 2021-04-23 Modulación de enzimas y vías con compuestos de sulfhidrilo y sus derivados (divisional exp. 2022-0531)

Country Status (18)

Country Link
US (2) US20230265204A1 (es)
EP (2) EP4400515A3 (es)
JP (3) JP2023522417A (es)
KR (1) KR20230005172A (es)
CN (1) CN115427443A (es)
AR (1) AR121918A1 (es)
AU (1) AU2021258475A1 (es)
BR (1) BR112022021203A2 (es)
CA (1) CA3178472A1 (es)
CL (2) CL2022002885A1 (es)
CR (2) CR20220531A (es)
IL (1) IL296664A (es)
MX (1) MX2022013173A (es)
PE (1) PE20230078A1 (es)
SA (1) SA522441031B1 (es)
TW (2) TWI908792B (es)
WO (1) WO2021214277A1 (es)
ZA (1) ZA202210643B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3334167A1 (de) 1983-09-21 1985-04-04 Siemens AG, 1000 Berlin und 8000 München Halbleiterdiode
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
WO1994028418A1 (en) 1993-05-28 1994-12-08 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
GB9717926D0 (en) 1997-08-22 1997-10-29 Micromass Ltd Methods and apparatus for tandem mass spectrometry
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AU2463299A (en) 1998-01-23 1999-08-09 Analytica Of Branford, Inc. Mass spectrometry from surfaces
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
EP2359685B1 (en) * 2001-12-27 2013-12-04 GlycoFi, Inc. Methods to engineer mammalian-type carbohydrate structures
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
PL2118300T3 (pl) 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
SG10201808730VA (en) 2007-04-03 2018-11-29 Amgen Res Munich Gmbh Cross-species-specific binding domain
ES2695999T3 (es) 2007-10-12 2019-01-11 Hoffmann La Roche Expresión de proteínas a partir de múltiples ácidos nucleicos
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2010069603A1 (en) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
KR20110013687A (ko) 2009-08-03 2011-02-10 삼성모바일디스플레이주식회사 유기전계발광표시장치 및 그의 구동방법
MX2012003396A (es) 2009-09-16 2012-04-10 Genentech Inc Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos.
CN103796679B (zh) 2011-06-23 2016-10-19 比奥根国际神经科学公司 抗-α突触核蛋白结合分子
EP2747781B1 (en) 2011-08-23 2017-11-15 Roche Glycart AG Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
EP3321286B1 (en) 2011-08-23 2021-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
HRP20230065T1 (hr) 2011-10-28 2023-03-03 Prothena Biosciences Limited Humanizirana protutijela koja prepoznaju alfa-sinuklein
SG11201404321YA (en) 2012-01-27 2014-08-28 Neotope Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
JP2017501848A (ja) * 2013-11-19 2017-01-19 プロセナ バイオサイエンシーズ リミテッド 便秘症状からのレビー小体病の免疫療法のモニター
CA2924268C (en) 2013-11-21 2021-05-18 F. Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
WO2015128314A1 (en) * 2014-02-27 2015-09-03 F. Hoffmann-La Roche Ag Modulation of cell growth and glycosylation in recombinant glycoprotein production
RS65573B1 (sr) 2014-08-04 2024-06-28 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije
CN110603266A (zh) * 2016-06-02 2019-12-20 豪夫迈·罗氏有限公司 用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
EA201991720A1 (ru) * 2017-02-17 2020-01-20 Бристол-Маерс Сквибб Компани Антитела к альфа-синуклеину и их применения
JP2020528061A (ja) * 2017-07-26 2020-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法
EP3833435B1 (en) * 2018-08-09 2025-09-24 F. Hoffmann-La Roche AG Determination of parkinson's disease

Also Published As

Publication number Publication date
EP4400515A3 (en) 2024-10-23
US20230265204A1 (en) 2023-08-24
BR112022021203A2 (pt) 2022-12-06
CL2025000038A1 (es) 2025-05-23
EP4400515A2 (en) 2024-07-17
US20250353922A1 (en) 2025-11-20
MX2022013173A (es) 2022-11-30
AU2021258475A1 (en) 2022-10-20
WO2021214277A1 (en) 2021-10-28
AR121918A1 (es) 2022-07-20
CN115427443A (zh) 2022-12-02
CA3178472A1 (en) 2021-10-28
IL296664A (en) 2022-11-01
CL2022002885A1 (es) 2023-06-16
PE20230078A1 (es) 2023-01-11
SA522441031B1 (ar) 2025-05-15
JP2023522417A (ja) 2023-05-30
TW202206459A (zh) 2022-02-16
CR20250142A (es) 2025-10-30
TWI908792B (zh) 2025-12-21
JP2025157400A (ja) 2025-10-15
TW202547878A (zh) 2025-12-16
ZA202210643B (en) 2023-06-28
KR20230005172A (ko) 2023-01-09
EP4139349A1 (en) 2023-03-01
JP2025072512A (ja) 2025-05-09

Similar Documents

Publication Publication Date Title
Cho et al. Engineering advanced logic and distributed computing in human CAR immune cells
Bayer An overview of monoclonal antibodies
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
CR20250142A (es) Modulación de enzimas y vías con compuestos de sulfhidrilo y sus derivados (divisional exp. 2022-0531)
JP2021106595A (ja) 造血幹細胞における遺伝子編集のための方法および組成物
EP2548574B1 (en) New humanized anti-cd20 monoclonal antibody
UA116614C2 (uk) Антитіло до фактора d і його застосування
WO2021262910A3 (en) Tubulysins and protein-tubulysin conjugates
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
AU2015358615A1 (en) Anti-CD38 antibodies for treatment of acute myeloid leukemia
WO2019204462A3 (en) Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
KR20060038461A (ko) Ｎｋ 세포 강화 화합물을 사용하여 치료용 항체의 효율을높이는 방법 및 조성물
MY208067A (en) Tubulysins and protein-tubulysin conjugates
Hidalgo et al. Switchable CAR T cell strategy against osteosarcoma
ZA202302392B (en) Antibodies against ilt2 and use thereof
WO2020172482A3 (en) Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumors
WO2020142740A8 (en) Treatment of sjogren's disease with nuclease fusion proteins
ZA202110285B (en) Antibodies and methods of use
WO2022241151A3 (en) Chimeric antigen receptor t cell therapy
CN117321078A (zh) 针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药
MX2022001403A (es) Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.
JP2019500878A (ja) モノクローナル抗体組成物中の高分子量種、酸性荷電種、及び断片の低減
CN101287493A (zh) 采用cd4结合肽和辐射的疗法
TW201920659A (zh) 用於治療免疫療法的副作用之方法
JP2023542065A (ja) 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ